Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference.

The company's President and Chief Executive Officer, Sean P. Bohen, M.D., Ph.D., will deliver a presentation on March 5, 2025, at 10:30 a.m. ET.

Investors and interested parties can access a live webcast of the presentation and related materials through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be made available at the same location following the presentation.

News Market Reaction – OLMA

-1.55%

1 alert

-1.55% News Effect

On the day this news was published, OLMA declined 1.55%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45^th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET.

A live webcast of the presentation and any accompanying materials will be available under the Events and Presentations section of Olema’s Investor Relations website at ir.olema.com. A recording of the presentation will be made available in the same location.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When is Olema Pharmaceuticals (OLMA) presenting at the TD Cowen Health Care Conference 2025?

Olema Pharmaceuticals will present at the TD Cowen Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET.

How can investors watch Olema Pharmaceuticals' (OLMA) TD Cowen conference presentation?

Investors can watch the live webcast through the Events and Presentations section of Olema's Investor Relations website at ir.olema.com. A recording will also be available afterward.

What is the focus area of Olema Pharmaceuticals (OLMA)?

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond.

Who will represent Olema Pharmaceuticals (OLMA) at the 2025 TD Cowen Healthcare Conference?

Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Pharmaceuticals, will present at the conference.